Kinetics of anti- Aspergillus spp. IgG antibodies in COVID-19-associated pulmonary aspergillosis

Clicks: 4
ID: 327346
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #160 of 163 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 163 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
COVID-19-associated pulmonary aspergillosis (CAPA) is a recognized fungal superinfection, but diagnosis remains difficult due to non-specific clinical and radiological findings. While anti-Aspergillus spp. IgG antibodies (AspAb) are used for chronic aspergillosis diagnosis, their role in this context is unclear. We described AspAb kinetics in CAPA patients hospitalized in intensive care unit (ICU). We performed a retrospective study at Lille University Hospital from February 2020 to December 2021, enrolling ICU SARS-CoV-2 patients. Patients were included if they had at least one positive mycological marker - direct examination, culture, galactomannan antigen (GM) or Aspergillus fumigatus qPCR in bronchoalveolar lavage and/or serum - along with clinical and radiological findings consistent with CAPA, as defined by the 2020 ECMM/ISHAM consensus criteria. Among 898 patients, 95 (10.6%) had at least one positive mycological marker; 47 fulfilled CAPA criteria (5.2%), and 43 had at least one AspAb measurement. One-quarter of CAPA patients (23.3%, 10 patients) had at least one positive AspAb measurement (one of whom had only one measurement). Among AspAb-positive patients, 7 (70.0%) seroconverted a mean of 8.3 days (SD, 8.5) after CAPA diagnosis; one had documented positivity prior to hospitalization. Seven patients (70.0%) reached AspAb rate ≥ 80 AU/mL. These results are the first observed in CAPA patients and need to be confirmed in a larger cohort of non-neutropenic patients hospitalized in ICU with viral pneumonia.
Reference Key
openalex_W7204656961 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Camille Cordier, Chloë Lemaire, Fanny Vuotto, Mahdi Ouafi, Séverine Loridant, Gaetan Piga, Jordan Leroy, Julien Poissy, Boualem Sendid, Anahita Rouzé, Marjorie Cornu
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag089
URL
https://doi.org/10.1093/mmy/myag089
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.